Phibro Animal Health Corporation — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, with comparisons to fiscal years 2022 and 2021. The provided filing is not a 2022 Q4 filing; it is the FY2023 annual report and includes quarterly data through June 30, 2023.
Business Context
Phibro is a global animal health, mineral nutrition and performance products company operating in more than 80 countries with approximately 4,000 customers and about 770 product lines. Its three segments are Animal Health, Mineral Nutrition and Performance Products.
- Animal Health: Antibacterials, anticoccidials, nutritional specialties and vaccines for poultry, swine, cattle, dairy, aquaculture and companion animals.
- Mineral Nutrition: Trace-mineral products, primarily serving North American feed and livestock customers.
- Performance Products: Specialty ingredients for personal care, industrial chemical and chemical catalyst applications.
Key Financial Metrics
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net sales | $977.9 million | $942.3 million | Up 4% |
| Gross profit | $298.2 million | $285.4 million | Up 4% |
| Gross margin | 30.5% | 30.3% | Up 20 bps |
| Operating income | $71.8 million | $79.0 million | Down 9% |
| Net income | $32.6 million | $49.2 million | Down 34% |
| Diluted EPS | $0.81 | $1.21 | Down $0.40 |
| Adjusted EBITDA | $112.8 million | $111.1 million | Up 2% |
| Adjusted net income | $49.0 million | $53.2 million | Down 8% |
| Adjusted diluted EPS | $1.21 | $1.31 | Down 8% |
| Net cash from operating activities | $13.3 million | $31.6 million | Down $18.3 million |
| Capital expenditures | $51.8 million | $37.0 million | Up $14.8 million |
Segment Performance
| Segment | FY2023 Sales | Sales Change | FY2023 Adjusted EBITDA | EBITDA Change |
|---|---|---|---|---|
| Animal Health | $659.9 million | Up 9% | $136.1 million | Up 10% |
| Mineral Nutrition | $242.7 million | Down 6% | $17.4 million | Down 28% |
| Performance Products | $75.4 million | Down less than 1% | $9.3 million | Up 7% |
Animal Health growth reflected higher demand for medicated feed additives, nutritional specialties, vaccines and companion-animal products. Mineral Nutrition declined because of lower trace-mineral demand, despite higher average selling prices. Performance Products were affected by weaker demand for personal-care ingredients and copper-related products.
Margins, Profitability and Unusual Items
- Gross profit increased despite higher raw-material and logistics costs, primarily because of stronger Animal Health demand.
- SG&A increased 10% to $226.4 million. FY2023 included $6.9 million of environmental remediation and Omega Chemical Site settlement-related costs.
- Operating income declined because SG&A growth exceeded the increase in gross profit.
- Net interest expense increased 29% to $15.3 million because of higher debt and floating interest rates.
- Foreign currency results shifted from a $5.2 million gain in FY2022 to a $2.5 million loss in FY2023.
- The effective tax rate increased to 39.7% from 32.0%, partly due to geographic earnings mix, GILTI and other one-time tax items.
Cash Flow, Liquidity and Debt
- Cash and cash equivalents were $41.3 million and short-term investments were $40.0 million at June 30, 2023, for total cash and short-term investments of $81.3 million, down from $91.2 million.
- Working capital was $350.7 million, and the reported current-asset-to-current-liability ratio was 3.28:1.
- Operating cash flow declined primarily because of inventory investment, lower accounts payable and other working-capital uses.
- Investing cash use was $74.0 million, including $51.8 million of capital expenditures and $15.0 million for additional land and a building.
- Outstanding debt at June 30, 2023 included $273.8 million under the 2021 Term A Loan, $50.0 million under the 2023 Incremental Term Loan, $141.0 million under the revolver and $11.7 million under the 2022 Term Loan.
- The revolver commitment was $310.0 million; $166.5 million remained available after borrowings and letters of credit, subject to debt-facility restrictions.
- The 2021 Credit Facilities mature in April 2026; the 2022 Term Loan matures in September 2027. The company was in compliance with its financial covenants at June 30, 2023.
- Management stated that cash, operating cash flow and financing availability should support liquidity for at least the next twelve months, while noting that adverse operating results or covenant violations could impair funding flexibility.
Material Changes and Outlook
- Animal Health continued to be the principal growth and profit driver, while Mineral Nutrition weakened materially.
- The company continued investments in vaccine production capacity in Ireland and Brazil, companion-animal products, microbial products and vaccine technologies.
- Management identified global livestock production, protein demand, emerging markets, product development and operational efficiency as long-term growth drivers.
- No formal quantitative revenue or earnings guidance is provided in the filing text.
- In July 2023, the company entered into a pension annuity transaction funded with pension assets. It expects to record approximately $10.4 million of pension-settlement expense and a tax benefit of approximately $2.7 million in the quarter ending September 30, 2023.
Key Risks, Contingencies and Governance Matters
- Antibacterials and related products represented approximately 40% of net sales. Regulatory restrictions, changing consumer perceptions or product bans could materially affect results.
- Mecadox, containing carbadox, remains subject to FDA regulatory scrutiny. FY2023 Mecadox sales were approximately $20 million; loss of approval would negatively affect results.
- Environmental liabilities included approximately $8.5 million of accrued remediation obligations at June 30, 2023. The Omega Chemical Site settlement contemplated cash payments through February 2024 and required formal regulatory and court approval.
- Raw-material inflation, supply interruptions, customer consolidation, generic competition, weather, animal disease outbreaks, climate effects, foreign exchange and geopolitical risks may affect demand, costs and operations.
- The company had significant international exposure, including manufacturing and sales operations in Israel and Brazil, and sales to Russia and Ukraine represented approximately 1% of consolidated sales.
- Class B shares carry ten votes per share. BFI and related Bendheim interests controlled approximately 90.9% of combined voting power as of August 25, 2023, making Phibro a controlled company.
- The company paid $19.4 million of dividends in FY2023 and declared a $0.12-per-share dividend payable September 27, 2023, subject to applicable restrictions and Board approval.
- PricewaterhouseCoopers issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls.
Investor Verification Checklist
- Verify the intended period: the filing is for FY2023, not 2022 Q4.
- Reconcile GAAP earnings and cash flow with non-GAAP Adjusted EBITDA and adjusted net income, especially the $6.9 million environmental item and foreign-currency adjustments.
- Assess debt maturities, floating-rate exposure, revolver availability and covenant headroom before the April 2026 maturity.
- Monitor Mineral Nutrition demand, inventory levels and raw-material costs.
- Track FDA action concerning Mecadox and broader antimicrobial restrictions.
- Review the status and remaining payments of the Omega Chemical Site settlement and other environmental obligations.
- Evaluate the expected impact of the July 2023 pension settlement and the company’s ability to sustain dividends while funding capital expenditures.
- Consider the implications of concentrated voting control, potential Class B share conversion and the Rule 10b5-1 arrangement for up to 528,000 Class A shares.